ישראל - עברית - Ministry of Health

novo nordisk ltd., israel - eptacog alfa (activated) - אבקה להכנת תמיסה לזריקה - eptacog alfa (activated) 1 mg/vial - eptacog alfa (activated) - eptacog alfa (activated) - treatment of bleeding episodes and prevention of bleeding in those undergoing surgery of invasive procedures in the following patient goups : * in patients with congenital haemophilia with inhibitors to coagulation factors viii or ix > 5 bu, * in patients with congenital haemophilia who are expected to have a high anamnestic response to factor viii or factor ix administration, * in patients with acquired haemophilia, in patients with congenital fvii deficieny, * in patients with glanzmann's thropnbastenia with antibodies to gp iib-iiia and/or hla, and with past or present refractoriness to platelet transfusions.

ישראל - עברית - Ministry of Health

novo nordisk ltd., israel - eptacog alfa (activated) - אבקה להכנת תמיסה לזריקה - eptacog alfa (activated) 2 mg/vial - eptacog alfa (activated) - eptacog alfa (activated) - treatment of bleeding episodes and prevention of bleeding in those undergoing surgery of invasive procedures in the following patient goups : * in patients with congenital haemophilia with inhibitors to coagulation factors viii or ix > 5 bu, * in patients with congenital haemophilia who are expected to have a high anamnestic response to factor viii or factor ix administration, * in patients with acquired haemophilia, in patients with congenital fvii deficieny, * in patients with glanzmann's thropnbastenia with antibodies to gp iib-iiia and/or hla, and with past or present refractoriness to platelet transfusions.

ישראל - עברית - Ministry of Health

novo nordisk ltd., israel - eptacog alfa (activated) - אבקה להכנת תמיסה לזריקה - eptacog alfa (activated) 5 mg/vial - eptacog alfa (activated) - eptacog alfa (activated) - treatment of bleeding episodes and prevention of bleeding in those undergoing surgery of invasive procedures in the following patient goups : * in patients with congenital haemophilia with inhibitors to coagulation factors viii or ix > 5 bu, * in patients with congenital haemophilia who are expected to have a high anamnestic response to factor viii or factor ix administration, * in patients with acquired haemophilia, in patients with congenital fvii deficieny, * in patients with glanzmann's thropnbastenia with antibodies to gp iib-iiia and/or hla, and with past or present refractoriness to platelet transfusions.

ישראל - עברית - Ministry of Health

glaxo smith kline (israel) ltd - hepatitis a virus antigen, inactivated - תרחיף להזרקה - hepatitis a virus antigen, inactivated 1440 e.l.u/ml - hepatitis a, inactivated, whole virus - hepatitis a, inactivated, whole virus - active immunisation against infections caused by hepatitis a virus.the vaccine is particularly indicated for those at increased risk of infection or transmission.

ישראל - עברית - Ministry of Health

glaxo smith kline (israel) ltd - hepatitis a virus antigen, inactivated - תרחיף להזרקה - hepatitis a virus antigen, inactivated 720 e.l.u / 0.5 ml - hepatitis a, inactivated, whole virus - hepatitis a, inactivated, whole virus - havrix junior monodose vaccine is indicated for active immunisation against hav infection. the vaccine is particularly indicated for those at increased risk of infection or transmission.

ישראל - עברית - Ministry of Health

merck sharp & dohme (israel - 1996) company ltd, israel - hepatitis a virus antigen, inactivated - תרחיף להזרקה - hepatitis a virus antigen, inactivated 25 units / 0.5 ml - hepatitis a, inactivated, whole virus - hepatitis a, inactivated, whole virus - vaqta is indicated for active pre-exposure prophylaxis against disease caused by hepatitis a virus in children and adolescents 12 months of age and older .

ישראל - עברית - Ministry of Health

merck sharp & dohme (israel - 1996) company ltd, israel - hepatitis a virus antigen, inactivated - תרחיף להזרקה - hepatitis a virus antigen, inactivated 50 u/ml - hepatitis a, inactivated, whole virus - hepatitis a, inactivated, whole virus - vaqta is indicated for active pre-exposure prophylaxis against disease caused by hepatitis a virus in persons 2 years of age and older.

ישראל - עברית - Ministry of Health

glaxo smith kline (israel) ltd - rabies, inactivated, whole virus - אבקה וממס להכנת תמיסה להזרקה - rabies, inactivated, whole virus 2.5 iu/ml - rabies, inactivated, whole virus - rabies, inactivated, whole virus - active immunization against rabies.

ישראל - עברית - Ministry of Health

sanofi israel ltd - rabies, inactivated, whole virus - אבקה וממס להכנת תרחיף להזרקה - rabies, inactivated, whole virus 2.5 iu - rabies, inactivated, whole virus - rabies, inactivated, whole virus - prevention of rabies in children and adults. it can be used before and after exposure, as a primary vaccination or as a booster dose.

ישראל - עברית - Ministry of Health

pfizer pharmaceuticals israel ltd - encephalitis, tick borne, inactivated, whole virus - תרחיף להזרקה - encephalitis, tick borne, inactivated, whole virus 2.4 mcg / 0.5 ml - encephalitis, tick borne, inactivated, whole virus